AzTrials
AzTrials

HPV 16+ Recurrent or Metastatic CancerPhase 1NCT07081984

Study of TI-0093 Injection With Recurrent/Metastatic HPV-16 Positive Solid Tumors

A Phase 1 study testing therapeutic tumor vaccine in people with HPV 16+ Recurrent or Metastatic Cancer and HNSCC, run by Therorna at 1 site in China.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This is a phase I, open-label, dose escalation study to assess the safety, tolerability, efficacy and immunogenicity of TI-0093 injection in patients with recurrent or metastatic HPV-16 positive solid tumors. Read more about this study

Who is it for?
Ages 18 to 75 years
What is being tested?
therapeutic tumor vaccine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
12 participants
Where
1 siteChina
Study dates
11 Nov 2025to 31 Jul 2027
Phase
Phase 1
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients must meet all the following inclusion criteria to be eligible for participation in this study:
  • The patient provides written informed consent for the study.
  • Willing to comply with the visit plans, treatment plans, and other requirements of the study schedule.
  • Previous HPV16+ solid tumors.
  • 18 to 75 years of age at the time of informed consent.
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 with no deterioration over the previous 2 weeks.
Show all 15Show fewer
  • Estimated life expectancy of more than 12 weeks.
  • Previous HPV16 positive head and neck, cervical and other carcinoma patients with recurrent or metastatic disease, who have progressed after standard therapies, or for whom no further standard therapies are available.
  • Patients should have at least 1 measurable lesion at baseline according to the definition of RECISTv1.1.
  • Absolute neutrophil count ≥ 1.5 ×10^9/L, without the use of granulocyte colony stimulating factors such as filgrastim within 2 weeks prior to study treatment. Platelet count ≥ 100 × 10^9/L without transfusion within 2 weeks (≤ 14 days) prior to study treatment. Hemoglobin ≥ 9 g/dL without transfusion or erythropoietin within 2 weeks (≤ 14 days) prior to study treatment.
  • Aspartate transaminase and alanine aminotransferase ≤ 3 × upper limit of normal (ULN) (patients with liver metastasis < 5 × ULN), and total bilirubin ≤ 1.5 × ULN (patients with Gilbert's Syndrome ≤ 3 × ULN).
  • Adequate renal function defined by either a creatinine clearance ≥ 45 mL/min (by Cockcroft-Gault formula) or serum creatinine < 1.5 × ULN.
  • Prothrombin time ≤ 1.5 × ULN; activated partial thromboplastin time ≤ 1.5 × ULN; international normalized ratio ≤ 1.5 × ULN.
  • Left ventricular ejection fraction ≥ 50% measured by echocardiogram.
  • Females of childbearing potential and males whose partners are of childbearing potential agree to the use effective contraception from signing informed consent form to 90 days after the last dose of TI-0093 injection. The test results of HCG of females with childbearing potential should be negative within 7 days prior to the first dose of TI-0093 injection.

Who cannot join

  • Patients who meet any of the following exclusion criteria cannot be enrolled:
  • History of any therapeutic HPV vaccination. History of any live viral vaccine or attenuated live vaccine therapies within 4 weeks prior to the first dose of TI-0093 injection.
  • History of life-threatening hypersensitivity or known to be allergic to any ingredients contained in the TI-0093 injection.
  • Females who are pregnant or breastfeeding. Patients who plan to donate sperm or eggs from signing informed consent form to 90 days post the last dose of TI-0093 injection.
  • Patients with underlying comorbidity will be excluded:
  • Active known second malignancy, except for any of the following: basal cell carcinoma, squamous cell skin cancer, in situ cervical cancer and non-muscle invasive bladder cancer, which were recovered from adequate clinical treatment, and other cancers treated by surgery alone whose disease-free survival were 5 years and above.
Show all 31Show fewer
  • Meningeal metastases, spinal cord compression or symptomatic brain metastases within 28 days prior to the first dose of TI-0093 injection (except for patients with prior brain metastases who were treated and clinically stable for 4 weeks without corticosteroid or antiepileptic drug treatment).
  • History of severe pneumonia such as interstitial lung disease within 6 months prior to the first dose of TI-0093 injection.
  • Major surgery within 4 weeks prior to the first dose of TI-0093 injection. E. Deep vein thrombosis or arterial embolism such as pulmonary embolism within 6 months prior to the first dose of TI-0093 injection.
  • Active bleeding symptoms or diseases such as active hemoptysis, gastrointestinal bleeding and hemorrhagic gastric ulcer within 28 days prior to the first dose of TI-0093 injection.
  • Alcohol dependence (averagely more than 2 units of alcohol per day (1 unit = 360 ml of beer, 45 ml of 40% liquor, or 150 ml of wine) which may affect safety assessment judged by the investigator. Drug abuse but unable to quit or mental disorders.
  • Patients with active autoimmune disease or symptoms that required systemic use of pharmacologic dose of corticosteroid and/or immunosuppressant within 4 weeks prior to the first dose of TI-0093 injection. Exceptions are patients with vitiligo, resolved asthma/atopy, and type 1 diabetes mellitus or hypothyroidism that can be managed by replacement therapy.
  • Severe or uncontrolled systemic diseases above:
  • Grade 2 and above myocardial infarction, grade 2 and above myocardial ischemia, or grade 2 and above heart failure based on New York Heart Association (NYHA) classification within 6 months prior to the first dose of TI-0093 injection. Arrhythmia such as QTc ≥ 480ms needs to be treated and uncontrolled hypertension during the screening period.
  • Any active or uncontrolled infection such as uncontrolled diabetes (defined as HbA1c ≥ 7.5%), asthma, clinically active diverticulitis, abdominal abscess or gastrointestinal obstruction during the screening period.
  • Active hepatitis B (both hepatitis B virus surface antigen being positive and hepatitis B virus carriers with a viral load > 200 IU/ml), active hepatitis C (both HCV antibody and RNA testing being positive), positive for treponema pallidum in serum or active tuberculosis during the screening period.
  • Known positive test results for human immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS). Prior organ allograft transplantations or allogeneic peripheral blood stem cell (PBSC) or bone marrow (BM) transplantation.
  • History of gastrointestinal perforation, gastrointestinal fistula or female reproductive tract fistula within 6 months prior to the first dose of TI-0093 injection. Except for those recovered after treatment judged by the investigator.
  • Pleural effusion, ascites or pericardial effusion requires puncture aspiration or drainage within 2 weeks prior to the enrollment.
  • Grade 3 and above immune-related AEs or any immune-related AE lead to discontinuation of prior immunotherapy.
  • Any previous AE has not been improved to Grade 1 and below (except for patients with hair loss, grade 2 peripheral neurotoxicity, stable hypothyroidism after hormone replacement therapy or other AEs with no safety risk judged by the investigator).
  • Asplenia or insufficiency of spleen function caused by infarct of spleen or thrombosis of splenic vein.
  • Systemic treatment with corticosteroids (≥ 10 mg/day prednisone or equivalent) or other immunosuppressive medications within 14 days prior to the first dose of TI-0093 injection.
  • Washout period for any previous immunomodulatory drugs such as thymosin, interleukin-2, and interferon: last treatment is within 4 weeks prior to prior to the first dose of TI-0093 injection.
  • Washout period for any previous anticancer therapy prior to the first dose of TI-0093 injection:
  • Last treatment is within 4 weeks for chemotherapy, biologic therapy, target therapy or immunotherapy.
  • Last treatment is within 2 weeks for radiotherapy, endocrine therapy or oral fluorouracil drugs.
  • Last treatment is within 7 days for anticancer Chinese medicine.
  • Last treatment is within 6 weeks for nitrosoureas and mitomycin.
  • Last treatment with investigational product is within 5 half-lives or 4 weeks (which is longer).
  • Any other disease or clinically significant abnormality in laboratory parameters, which in the judgment of the investigator might compromise the safety of the patient or integrity of the study, interfere with the patient participation in the trial or compromise the trial objectives.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Ye Guo contact

0086-457-13501678472

pattrickguo@gmail.com

The Drug Clinical Trial Institution of Shanghai East Hospital contact

021-38804518-28329 ext. 021-2033453

shdfgcp@163.com

China1 site, 1 recruiting

  • Shanghai East Hospital

    Shanghai

    Yan Shi, 021-38804518, austainsy@163.com

    Recruiting

Other trials in China

About this study

Official title: A Phase I Clinical Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of TI-0093 Injection in Patients With Recurrent/Metastatic HPV-16 Positive Solid Tumors

This is a phase I, open-label, dose escalation study to assess the safety, tolerability, efficacy and immunogenicity of TI-0093 injection in patients with recurrent or metastatic HPV-16 positive solid tumors.

The primary objectives of the study are to assess safety and tolerability of TI-0093 injection in patients with recurrent or metastatic solid tumors, and to determine the maximum tolerated doses (MTDs) and recommended Phase 2 doses (RP2Ds) of TI-0093 injection.

Read the detailed description

All potential study candidates will provide informed consent and undergo screening procedures to determine their study eligibility. After a screening period of up to 28 days, qualified patients will be enrolled to receive their assigned dose of TI-0093 injection. Patients will receive a total of five doses of TI-0093 administered muscularly on Day1, Day8, Day15, Day29 and Day43, respectively. Dose-limiting toxicities (DLTs) will be assessed for at least 28 days after the first dose of a given regimen. During the study, patients will be evaluated for safety, toxicity, immunogenicity, ORR, DOR, DCR, and PFS per protocol.

Being tested
therapeutic tumor vaccine
Keywords
Therapeutic tumor vaccine, Circular RNA
Medical subject headings
Neoplasm Metastasis, Squamous Cell Carcinoma of Head and Neck, Uterine Cervical Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • therapeutic tumor vaccineBiological

    TI-0093 injection will be administered intramuscularly on Day1, Day8, Day15, Day29 and Day43.

Study groups in NCT07081984
Study groupRoleWhat they receive
TI-0093 injectionExperimentalTherapeutic tumor vaccine: TI-0093 injection. Different dose levels of TI-0093 injection. Route of administration: Muscle
Receives: Biological: therapeutic tumor vaccine

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Adverse Events (AEs)

    The safety profiles of TI-0093 injection will be assessed in terms of severity, seriousness, frequency of AEs, laboratory results, vital signs, physical examinations, and 12-lead electrocardiogram of the patients enrolled in the study.

    Measured: From enrollment to 28 days post the last dose of TI-0093 injection

  2. DLTs

    DLTs will be assessed for at least 28 days after the first dose TI-0093 injection of a given regimen. Toxicities will be assessed by the National Cancer Institute Common Terminology Criteria for AEs (NCI CTCAE) v5.0.

    Measured: From enrollment to 3 months.

  3. RP2D

    The RP2D will be determined based on the observation of MTD.

    Measured: From enrollment to 3 months.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Jul 2025
  2. Study start11 Nov 2025
  3. Primary completion20 Sep 2026 (estimated)
  4. Study completion31 Jul 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential
Masking
None (open label)
Enrolment
12 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07081984
Sponsor's protocol ID
0093101
Status last verified
Nov 2025
First submitted
11 Jul 2025
Last updated
24 Nov 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Confidentiality based on clinical development strategies of TI-0093 injection, IPD sharing will not be planned.

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing therapeutic tumor vaccine in people with HPV 16+ Recurrent or Metastatic Cancer and HNSCC, run by Therorna at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 15 inclusion and 31 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 24 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Ye Guo (0086-457-13501678472, pattrickguo@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Adverse Events (AEs) (time frame: From enrollment to 28 days post the last dose of TI-0093 injection). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07081984.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Nov 2025.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in